A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
NCT06246513 · EMERGENE Phase 3Active, not recruiting
- Lead sponsor
- Sarepta Therapeutics, Inc. (Industry)
- Enrollment
- 17 (actual)
- Start date
- 15 Jan 2024
- Primary completion
- 4 Mar 2025 (actual)
- Study completion
- 30 Nov 2029
- Last update posted
- 2 Mar 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None
- Arms
- 1
Interventions
- SRP-9003 Biological
- Glucocorticoid Drug
Conditions and primary outcome
- Limb-girdle Muscular Dystrophy
Primary outcome
Cohort 1: Change from Baseline in β-SG Expression at Day 60 Post-dose as Measured by Immunofluorescence (IF) Percent β-SG Positive Fibers (Baseline, Day 60)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06246513.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06246513 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.